Disparities in patient share and characteristics between disease-modifying therapy-treated and - untreated people with multiple sclerosis in Germany: a claims data analysis from 2017 to 2022

One of the key insights from the study is the striking proportion of MS patients in Germany who remain untreated with disease-modifying therapies—despite available options. The data reveal notable differences tied to age, MS type, and geography, alongside contrasting patterns in healthcare utilization. These findings raise important questions about real-world treatment access and clinical decision-making.

By Stratil, A.-S., Papukchieva, S., Neß, N.-H., Wolf, I., Bayas, A., Flachenecker, P., & Friedrich, B. (2025) in Frontiers in Neurology 16, 1561810.